| Literature DB >> 32824073 |
Jihyun Lee1, Jiyoung Woo1, Ah Reum Kang1, Young-Seob Jeong1, Woohyun Jung2, Misoon Lee2, Sang Hyun Kim2.
Abstract
Hypotensive events in the initial stage of anesthesia can cause serious complications in the patients after surgery, which could be fatal. In this study, we intended to predict hypotension after tracheal intubation using machine learning and deep learning techniques after intubation one minute in advance. Meta learning models, such as random forest, extreme gradient boosting (Xgboost), and deep learning models, especially the convolutional neural network (CNN) model and the deep neural network (DNN), were trained to predict hypotension occurring between tracheal intubation and incision, using data from four minutes to one minute before tracheal intubation. Vital records and electronic health records (EHR) for 282 of 319 patients who underwent laparoscopic cholecystectomy from October 2018 to July 2019 were collected. Among the 282 patients, 151 developed post-induction hypotension. Our experiments had two scenarios: using raw vital records and feature engineering on vital records. The experiments on raw data showed that CNN had the best accuracy of 72.63%, followed by random forest (70.32%) and Xgboost (64.6%). The experiments on feature engineering showed that random forest combined with feature selection had the best accuracy of 74.89%, while CNN had a lower accuracy of 68.95% than that of the experiment on raw data. Our study is an extension of previous studies to detect hypotension before intubation with a one-minute advance. To improve accuracy, we built a model using state-of-art algorithms. We found that CNN had a good performance, but that random forest had a better performance when combined with feature selection. In addition, we found that the examination period (data period) is also important.Entities:
Keywords: anesthesia; biomedical sensor; deep learning; hypotension prediction; machine learning; vital records
Mesh:
Year: 2020 PMID: 32824073 PMCID: PMC7472016 DOI: 10.3390/s20164575
Source DB: PubMed Journal: Sensors (Basel) ISSN: 1424-8220 Impact factor: 3.576
The taxonomy of related studies on hypotension prediction.
| Study | Outcome | Outcome Type | Feature | Algorithm | Performance |
|---|---|---|---|---|---|
| Park et al. [ | Hypotension before 1 month after surgery for hemodialysis patients | Static, after surgery | Heart rate variability (DM, CAD, CHF, Age, UFR, iPTH, ARB or ACEI, CCB, b-blocker, Mean HR, RRI, SDNN, RMSSD, VLF, LF, HF, TP, LF/HF ratio) | Multivariate negative binomial model | AUC: 0.804 |
| Moghadam et al. [ | At least 5 min before hypotension | Dynamic | ABP (arterial blood pressure), HR, Sys, Dia, Resp, SpO2, PP, MAP, CO, MAP to HR ratio (MAP2HR), average of RR intervals on ECG time series (RR) | Logistic Regression (LR) | Accuracy: 95% |
| Kendale et al. [ | Hypotension within 10 min after induction | Static, at induction | Age, Sex, BMI, ASA Score, Medical comorbidities, Preoperative medication, Intraoperative medications, Mean peak inspiratory pressure, First mean arterial pressure, Time of day, non-invasive and invasive blood pressure | LR, Support Vector Machine, Naïve Bayes, K-Nearest Neighbor, Linear Discriminant Analysis, Random Forest, Neural Network, Gradient Boosting Algorithm | Sensitivity: 64% |
| Lin et al. [ | Hypotension within 15 min after induction for spinal anesthesia | Static, at induction | Age, Gender, Weight, Height, Hematocrit, ASA score, Basal SBP, Basal DBP, Basal HR, History of hypertension, History of diabetes, Surgical category, Emergency, Dose of local anesthetics | LR, ANN, Simplified ANN | Accuracy: 77.6% |
| Hatib et al. [ | Hypotension at least within 5 min | Dynamic | 3022 features from arterial pressure waveform: Signal features, floTrac features, COTrek features, complexity features, Baroeflex features, variability features, spectral features, Delta change features | LR | Sensitivity: 86.8% |
RRI: R-R interval, SDNN: standard deviation of N-N interval, RMSSD: squared root of the mean squared differences of successive N-N interval, VLF: Very low frequency, LF: low frequency, HF: high frequency, TP: total power, Sys: systolic blood pressure, Dia: diastolic blood pressure, Resp: respiration rate, PP: pulse pressure, CO: cardiac output, MAP2HR: Map-to-HR ratio.
Figure 1Vital Recorder.
Data description.
| Data Source | Categories | Features |
|---|---|---|
| Electronic Health Record | Demographic data | Age |
| Comorbidities | Cardiovascular disease | |
| Respiratory disease | ||
| Gastrointestinal disease | ||
| Renal disease | ||
| Endocrine disease | ||
| Neurologic disease | ||
| Baseline | Systolic | |
| Mean | ||
| Diastolic | ||
| Vital Recorder | Noninvasive blood pressure | Systolic |
| Mean | ||
| Diastolic | ||
| Heart rate | Heart rate | |
| Mechanical ventilation data | Plethysmogram oxygen saturation | |
| End-tidal CO2 partial pressure | ||
| NMT_TOF_CNT | ||
| Respiratory rate | ||
| Tidal volume | ||
| Minute ventilation | ||
| Peak inspiratory pressure | ||
| Positive end expiratory pressure | ||
| Bispectral index | Spectral edge frequency | |
| Signal quality index | ||
| Electromyogram power | ||
| Total power | ||
| Bispectral index value | ||
| Anesthetic drug | Rate | |
| Plasma concentration | ||
| Effect-site concentration | ||
| Target concentration | ||
| Volume | ||
| Vasoactive drug administration | Vasopressor | |
| Vasodilator | ||
| Hypotension | Frequency | |
| Duration | ||
| Average duration |
Patient characteristics.
| Characteristic | All Patients (n = 82) | Hypotension (n = 151) | Non Hypotension (n = 131) | |
|---|---|---|---|---|
| Age | 54.7 (14.1) | 56.5 (14.5) | 52.6 (13.4) | 0.023 * |
| Sex (male) | 134 (47.5%) | 66 (43.7%) | 68 (51.9%) | 0.209 |
| Height | 162.1 (9) | 161.2 (8.7) | 163.2 (9.2) | 0.067 |
| Weight | 66.6 (12.4) | 64.5 (12) | 69.2 (12.5) | 0.002 ** |
| BMI | 25.2 (3.6) | 24.7 (3.6) | 25.8 (3.5) | 0.019 * |
| ASA classification -no | 0.426 | |||
| 1 | 95 (33.7%) | 48 (31.8%) | 47 (35.9%) | |
| 2 | 151 (54.6%) | 82 (54.3%) | 72 (55%) | |
| 3 | 33 (11.7%) | 21 (13.9%) | 12 (9.1%) | |
| Comorbidities | ||||
| Cardiovascular disease | ||||
| Hypertension | 97 (34.4%) | 55 (36.4%) | 42 (32.1%) | 0.520 |
| Atrial fibrillation | 2 (0.7%) | 2 (1.3%) | 0 | 0.500 |
| Coronary artery disease | 5 (1.8%) | 4 (2.6%) | 1 (0.8%) | 0.377 |
| Angina pectoris | 5 (1.8%) | 2 (1.3%) | 3 (2.3%) | 0.666 |
| Congestive heart failure | 1 (0.4%) | 1 (0.7%) | 1 (0.8%) | 1.000 |
| Valvular heart disease | 1 (0.4%) | 1 (0.7%) | 0 | 1.000 |
| Respiratory disease | ||||
| Asthma | 17 (6%) | 14 (9.3%) | 3 (2.3%) | 0.027* |
| Chronic obstructive pulmonary disease | 6 (2.1%) | 3 (2%) | 3 (2.3%) | 1.000 |
| Gastrointestinal disease | ||||
| Hepatitis | 3 (1.1%) | 2 (1.3%) | 1 (0.8%) | 1.000 |
| Liver cirrhosis | 6 (2.1%) | 3 (2%) | 3 (2.3%) | 1.000 |
| Viral carrier | 6 (2.1%) | 3 (2%) | 3 (2.3%) | 1.000 |
| Hepatitis B viral infection | 12 (4.3%) | 5 (3.3%) | 7 (5.3%) | 0.584 |
| Hepatitis C viral infection | 2 (0.7%) | 1 (0.7%) | 1 (0.8%) | 1.000 |
| Renal disease | ||||
| Chronic kidney injury | 0.209 | |||
| 2 | 1 (0.4%) | 0 | 1 (0.8%) | |
| 3 | 3 (1.1%) | 3 (2%) | 0 | |
| 4 | 1 (0.4%) | 1 (0.7%) | 0 | |
| End-stage renal disease | 1 (0.4%) | 1 (0.7%) | 0 | 1.000 |
| Endocrine disease | ||||
| Diabetes mellitus | 62 (22%) | 37 (24.5%) | 25 (19.1%) | 0.341 |
| Thyroid disease | 0.667 | |||
| 1 | 3 (1.1%) | 2 (1.3%) | 1 (0.8%) | |
| 2 | 4 (1.4%) | 1 (0.7%) | 3 (2.3%) | |
| 3 | 8 (2.8%) | 5 (3.3%) | 3 (2.3%) | |
| Neurologic disease | ||||
| Cerebrovascular disease | 12 (4.3%) | 8 (5.350 | 4 (3.1%) | 0.525 |
| Cerebral aneurysm | 1 (0.4%) | 0 | 1 (0.8%) | 0.465 |
| Baseline blood pressure -mmHg | ||||
| Systolic | 146.2 (23.8) | 140.8 (23.1) | 152.3 (23.1) | 0.001 *** |
| Mean | 105.9 (16) | 102.4 (16.2) | 109.9 (15) | 0.001 *** |
| Diastolic | 80.9 (10.5) | 78.3 (10.5) | 83.9 (9.8) | 0.001 *** |
| Noninvasive blood pressure -mmHg | ||||
| Systolic | 113.3 (22.7) | 105.4 (18.1) | 122.3 (24) | <0.001 *** |
| Mean | 84.3 (15.5) | 78.9 (12.5) | 90.4 (16.2) | <0.001 *** |
| Diastolic | 66.6 (12.5) | 62.7 (10.8) | 71.2 (12.8) | <0.001 *** |
| Heart rate -/min | 70.6 (13.1) | 70.8 (12.9) | 70.3 (13.3) | <0.001 |
| Mechanical ventilation data | ||||
| Plethysmogram oxygen saturation | 99.4 (1.5) | 99.4 (1.7) | 99.4 (1.5) | <0.001 *** |
| End-tidal CO2 partial pressure -% | 2.5 (1.5) | 2.5 (1.5) | 2.4 (1.5) | 0.001 *** |
| NMT_TOF_CNT | 2 (1.9) | 2.1 (1.9) | 1.9 (1.9) | 0.001 *** |
| Respiratory rate -/min | 15.7 (8.5) | 15.8 (8.6) | 15.5 (8.4) | 0.210 |
| Tidal volume -mL | 242.4 (172.3) | 242.3 (168.8) | 242.5 (176.2) | 0.318 |
| Minute ventilation -L/min | 4.2 (2.7) | 4.2 (2.7) | 4.2 (2.8) | 0.169 |
| Peak inspiratory pressure -cmH2O | 16.5 (7.4) | 16.1 (7) | 16.9 (7.7) | <0.001 *** |
| Positive end expiratory pressure -cmH2O | 3.1 (2.3) | 3.1 (2.2) | 3.1 (2.3) | 0.480 |
| Bispectral index | ||||
| Spectral edge frequency -Hz | 17.1 (3.7) | 17.1 (3.7) | 17 (3.7) | 0.001 *** |
| Signal quality index -Hz | 87.4 (16.2) | 88.6 (15.3) | 86.1 (17.2) | <0.001 *** |
| Electromyogram power -Hz | 30.5 (6.8) | 30.1 (6.4) | 30.9 (7.3) | 0.001 *** |
| Total power | 63 (7.5) | 63 (7.5) | 63.1 (7.4) | 0.007** |
| Bispectral index value | 51.8 (16.6) | 52.2 (16) | 51.5 (17.3) | 0.001 *** |
| Anesthetic drug | ||||
| Rate | ||||
| propofol -mg | 52.6 (91.4) | 47.6 (60.2) | 58.4 (117.2) | <0.001 *** |
| remifentanil -mg | 8.3 (33.6) | 7.2 (30.2) | 9.5 (37.2) | 0.001 *** |
| Plasma concentration | ||||
| propofol -mg | 5.3 (2.2) | 5.2 (2) | 5.4 (2.4) | <0.001 *** |
| remifentanil -mg | 2.1 (1.7) | 2.1 (1.6) | 2.2 (1.8) | 0.001 *** |
| Effect-site concentration | ||||
| propofol -mg | 4.9 (1.1) | 4.9 (0.9) | 4.9 (1.2) | <0.001 *** |
| remifentanil -mg | 1.7 (0.9) | 1.6 (0.9) | 1.7 (0.9) | <0.001 *** |
| Target concentration | ||||
| propofol -mg | 4.9 (1) | 4.9 (0.9) | 4.9 (1.1) | <0.001 *** |
| remifentanil -mg | 1.6 (1) | 1.5 (1) | 1.6 (1.1) | 0.001 *** |
| Volume | ||||
| propofol -mg | 6.7 (2.5) | 6.4 (4.9) | 7 (3) | <0.001 *** |
| remifentanil -mg | 0.8 (0.7) | 0.7 (0.4) | 0.9 (1) | <0.001 *** |
| Vasoactive drug administration -no | ||||
| Ephedrine | 4 (1.4%) | 4 (2.6%) | 0 | 0.126 |
| Phenylephrine | 1 (0.4%) | 1 (0.7%) | 0 | 1.000 |
| Nicardipine | 1 (0.4%) | 0 | 1 (0.8%) | 0.465 |
| Esmolol | 1 (0.4%) | 0 | 1 (0.8%) | 0.465 |
p < 0.001 ***, p < 0.01 **, p < 0.05 *.
Figure 2Preparing training data.
Figure 3Research framework of hypotension prediction composed of the deep learning model and the machine learning model, using raw features and statistical features.
Figure 4CNN architecture and vital record processing for CNN.
Specifications of parameters for CNN.
| Layer Type | Input Shape | Filter Shape | Activation | Parameters, # |
|---|---|---|---|---|
| Input | (60, 27, 1) | 0 | ||
| Conv2D | (58, 25, 32) | (3, 3) | Relu | 320 |
| Conv2D | (56, 23, 64) | (3, 3) | Relu | 18,496 |
| MaxPooling2D | (28, 11, 64) | (2, 2) | 0 | |
| Dropout | (28, 11, 64) | 0 | ||
| Flatten | (19712) | 0 | ||
| dense | (128) | Relu | 2,523,264 | |
| Dropout | (128) | 0 | ||
| dense | (1) | sigmoid | 129 |
Figure 5DNN architecture and vital record processing for DNN.
Feature sets from feature selection.
| All Features (106) | Feature Set A (45) | Feature Set B (20) | Feature Set C (29) |
|---|---|---|---|
| Age | 〮 | 〮 | 〮 |
| Sex | 〮 | ||
| Height | 〮 | ||
| Weight | 〮 | ||
| Body mass index | 〮 | ||
| ASA classification | |||
| Comorbidities | |||
| Cardiovascular disease | |||
| Hypertension | 〮 | ||
| Atrial fibrillation | |||
| Coronary artery disease | 〮 | ||
| Angina pectoris | 〮 | ||
| Congestive heart failure | 〮 | ||
| Valvular heart disease | 〮 | ||
| Respiratory disease | |||
| Asthma | 〮 | ||
| Chronic obstructive pulmonary disease | 〮 | ||
| Gastrointestinal disease | |||
| Hepatitis | 〮 | ||
| Liver cirrhosis | 〮 | ||
| Viral carrier | |||
| Hepatitis B viral infection | 〮 | ||
| Hepatitis C viral infection | 〮 | ||
| Renal disease | |||
| Chronic kidney injury | 〮 | ||
| End-stage renal disease | 〮 | ||
| Endocrine disease | |||
| Diabetes mellitus | |||
| HbA1c | 〮 | ||
| Thyroid disease | 〮 | ||
| Neurologic disease | |||
| Cerebrovascular disease | 〮 | ||
| Cerebral aneurysm | 〮 | ||
| Baseline blood pressure -mmHg | |||
| Systolic | 〮 | 〮 | |
| Mean | 〮 | 〮 | 〮 |
| Diastolic | 〮 | 〮 | |
| Noninvasive blood pressure | |||
| Systolic min | 〮 | 〮 | |
| Systolic max | 〮 | ||
| Systolic mean | 〮 | 〮 | |
| Systolic sd | |||
| Mean min | 〮 | 〮 | |
| Mean max | 〮 | ||
| Mean mean | 〮 | 〮 | |
| Mean sd | 〮 | ||
| Diastolic min | 〮 | ||
| Diastolic max | 〮 | ||
| Diastolic mean | 〮 | ||
| Diastolic sd | 〮 | ||
| Heart rate | |||
| min | |||
| max | |||
| mean | 〮 | 〮 | |
| Mechanical ventilation data | |||
| Respiratory rate min | |||
| Respiratory rate max | 〮 | ||
| Respiratory rate mean | 〮 | ||
| Tidal volume min | 〮 | 〮 | 〮 |
| Tidal volume max | 〮 | 〮 | |
| Tidal volume mean | |||
| Minute ventilation min | 〮 | ||
| Minute ventilation max | |||
| Minute ventilation mean | |||
| Peak inspiratory pressure min | 〮 | ||
| Peak inspiratory pressure max | 〮 | ||
| Peak inspiratory pressure mean | 〮 | 〮 | |
| Anesthetic drug | |||
| Rate | |||
| propofol min | 〮 | 〮 | 〮 |
| propofol max | 〮 | ||
| propofol mean | 〮 | ||
| Remifentanil min | 〮 | 〮 | |
| Remifentanil max | 〮 | 〮 | |
| Remifentanil mean | 〮 | 〮 | |
| Plasma concentration | |||
| propofol min | 〮 | 〮 | |
| propofol max | 〮 | ||
| propofol mean | |||
| Remifentanil min | |||
| Remifentanil max | |||
| Remifentanil mean | |||
| Effect-site concentration | |||
| propofol min | |||
| propofol max | 〮 | 〮 | |
| propofol mean | |||
| Remifentanil min | |||
| Remifentanil max | |||
| Remifentanil mean | |||
| Target concentration | |||
| propofol min | |||
| propofol max | |||
| propofol mean | |||
| Remifentanil min | 〮 | ||
| Remifentanil max | |||
| Remifentanil mean | |||
| Volume | |||
| propofol min | 〮 | 〮 | |
| propofol max | |||
| propofol mean | 〮 | ||
| Remifentanil min | 〮 | 〮 | 〮 |
| Remifentanil max | 〮 | ||
| Remifentanil mean | 〮 | 〮 | |
| Vasoactive drug administration | |||
| Ephedrine | |||
| Ephedrine volume | 〮 | ||
| Phenylephrine | 〮 | ||
| Phenylephrine volume | |||
| Nicardipine | 〮 | ||
| Nicardipine volume | |||
| Esmolol | 〮 | ||
| Esmolol volume | |||
| Hypotension | |||
| Frequency | 〮 | ||
| Duration | 〮 | ||
| Average duration | 〮 | 〮 |
Results on prediction performance using raw features.
| Feature Set | Performance Metrics | Random Forest | Xgboost | CNN | DNN | |
|---|---|---|---|---|---|---|
| Vital records | Accuracy | 70.32 | 64.15 | 72.24 | 63.25 | |
| Hypotension | Precision | 69.97 | 65.92 | 72.1 | 64.2 | |
| Recall | 78.28 | 69.15 | 79.04 | 72.12 | ||
| Vital records + EHR | Accuracy | 70.26 | 64.32 | 72.63 | 63.4 | |
| Hypotension | Precision | 69.84 | 66.14 | 72.69 | 64.38 | |
| Recall | 78.37 | 68.99 | 79.33 | 71.99 | ||
| Vital records + EHR + Vasoactive drug | Accuracy | 70.28 | 64.6 | 71.87 | 63.22 | |
| Hypotension | Precision | 69.82 | 66.5 | 72.92 | 64.32 | |
| Recall | 78.35 | 69.05 | 76.37 | 71.95 | ||
Results on prediction performance using statistical features.
| Random Forest | Xgboost | CNN | DNN | ||
|---|---|---|---|---|---|
| All features (97) | Accuracy | 70.76 | 65.15 | 65.33 | 69.03 |
| Precision | 72.16 | 67.37 | 68.29 | 70.78 | |
| Recall | 74.72 | 68.61 | 68.54 | 72.79 | |
| Feature set 1 | Accuracy | 65.26 | 61.75 | 60.34 | 63.03 |
| Precision | 67.02 | 64.81 | 63.79 | 65.57 | |
| Recall | 70.88 | 63.93 | 66.76 | 67.22 | |
| Feature set 2 | Accuracy | 74.89 | 69.84 | 67.95 | 73.85 |
| Precision | 75.8 | 71.5 | 70.69 | 73.72 | |
| Recall | 78.43 | 73.17 | 71.78 | 79.93 | |
| Feature set 3 | Accuracy | 73.06 | 68.28 | 68.95 | 73.84 |
| Precision | 74.59 | 70.19 | 74.11 | 75.73 | |
| Recall | 75.97 | 71.35 | 66.97 | 75.88 | |
Results on prediction performance with different lookback periods.
| 3 Min | 2 Min | 1 Min | ||
|---|---|---|---|---|
| Vital records + HER with CNN | Accuracy | 72.63 | 70.37 | 70.39 |
| Precision | 72.69 | 71.06 | 71.53 | |
| Recall | 79.33 | 75.64 | 74.64 | |
| Feature set 2 with RF | Accuracy | 74.89 | 71.45 | 74.42 |
| Precision | 75.8 | 72.16 | 72.66 | |
| Recall | 78.43 | 76.26 | 75.17 | |
Figure 6Feature importance.